{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:50:03Z","timestamp":1785894603658,"version":"3.56.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00280-008-0683-0","type":"journal-article","created":{"date-parts":[[2008,2,18]],"date-time":"2008-02-18T07:42:35Z","timestamp":1203320555000},"page":"937-948","source":"Crossref","is-referenced-by-count":23,"title":["Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo"],"prefix":"10.1007","volume":"62","author":[{"given":"Robert","family":"Mauritz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godefridus J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ietje","family":"Kathmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habte","family":"Teshale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Noordhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Comijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert M.","family":"Pinedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,19]]},"reference":[{"key":"683_CR1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-1-59259-725-3_20","volume-title":"Antifolate drugs in cancer therapy","author":"GW Aherne","year":"1999","unstructured":"Aherne GW, Brown S (1999) The role of uracil misincorporation in thymineless death. In: Jackman AL (ed) Antifolate drugs in cancer therapy. Humana Press, Totowa, pp 409\u2013421"},{"key":"683_CR2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1126\/science.1310359","volume":"255","author":"RG Anderson","year":"1992","unstructured":"Anderson RG, Kamen BA, Rothberg KG, Lacey SW (1992) Potocytosis: sequestration and transport of small molecules by caveolae. Science 255:410\u2013411","journal-title":"Science"},{"key":"683_CR3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.drup.2006.09.001","volume":"9","author":"YG Assaraf","year":"2006","unstructured":"Assaraf YG (2006) The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 9:227\u2013246","journal-title":"Drug Resist Updat"},{"key":"683_CR4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","volume":"26","author":"YG Assaraf","year":"2007","unstructured":"Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26:153\u2013181","journal-title":"Cancer Metastasis Rev"},{"key":"683_CR5","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood.V93.5.1643","volume":"93","author":"VM Belkov","year":"1999","unstructured":"Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S, Raimondi S, Pui CH, Relling MV, Evans WE (1999) Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 93:1643\u20131650","journal-title":"Blood"},{"key":"683_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001813-200501000-00001","volume":"16","author":"TS Benepal","year":"2005","unstructured":"Benepal TS, Judson I (2005) ZD9331: discovery to clinical development. Anticancer Drugs 16:1\u20139","journal-title":"Anticancer Drugs"},{"key":"683_CR7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/0006-2952(93)90604-U","volume":"46","author":"BJ Braakhuis","year":"1993","unstructured":"Braakhuis BJ, Jansen G, Noordhuis P, Kegel A, Peters GJ (1993) Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma. Biochem Pharmacol 46:2155\u20132161","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 1","key":"683_CR8","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1007\/s00280-003-0625-9","volume":"52","author":"E Chu","year":"2003","unstructured":"Chu E, Callender MA, Farrell MP, Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52(Suppl 1):S80\u2013S89","journal-title":"Cancer Chemother Pharmacol"},{"key":"683_CR9","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","volume":"16","author":"G Cocconi","year":"1998","unstructured":"Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, Van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 16:2943\u20132952","journal-title":"J Clin Oncol"},{"key":"683_CR10","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.1158\/1078-0432.CCR-05-0355","volume":"11","author":"PD Cole","year":"2005","unstructured":"Cole PD, Drachtman RA, Smith AK, Cate S, Larson RA, Hawkins DS, Holcenberg J, Kelly K, Kamen BA (2005) Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res 11:8089\u20138096","journal-title":"Clin Cancer Res"},{"key":"683_CR11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00280-005-0115-3","volume":"57","author":"PD Cole","year":"2006","unstructured":"Cole PD, Zebala JA, Alcaraz MJ, Smith AK, Tan J, Kamen BA (2006) Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy. Cancer Chemother Pharmacol 57:826\u2013834","journal-title":"Cancer Chemother Pharmacol"},{"key":"683_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1097-0215(19980105)75:1<125::AID-IJC19>3.0.CO;2-F","volume":"75","author":"G Corona","year":"1998","unstructured":"Corona G, Giannini F, Fabris M, Toffoli G, Boiocchi M (1998) Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer 75:125\u2013133","journal-title":"Int J Cancer"},{"key":"683_CR13","first-page":"810","volume":"53","author":"DS Duch","year":"1993","unstructured":"Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, Singer S (1993) Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53:810\u2013818","journal-title":"Cancer Res"},{"key":"683_CR14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","volume":"56","author":"H Elnakat","year":"2004","unstructured":"Elnakat H, Ratnam M (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56:1067\u20131084","journal-title":"Adv Drug Deliv Rev"},{"key":"683_CR15","doi-asserted-by":"crossref","first-page":"11721","DOI":"10.1158\/0008-5472.CAN-05-2034","volume":"65","author":"DD Gibbs","year":"2005","unstructured":"Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL (2005) BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 65:11721\u201311728","journal-title":"Cancer Res"},{"key":"683_CR16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","volume":"11","author":"M Hazarika","year":"2005","unstructured":"Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R (2005) Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11:982\u2013992","journal-title":"Clin Cancer Res"},{"key":"683_CR17","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/S0021-9258(17)43440-5","volume":"259","author":"GB Henderson","year":"1984","unstructured":"Henderson GB, Zevely EM (1984) Transport routes utilized by L1210 cells for the influx and efflux of methotrexate. J Biol Chem 259:1526\u20131531","journal-title":"J Biol Chem"},{"key":"683_CR18","first-page":"2532","volume":"59","author":"JH Hooijberg","year":"1999","unstructured":"Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532\u20132535","journal-title":"Cancer Res"},{"key":"683_CR19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/oxfordjournals.annonc.a059353","volume":"6","author":"AL Jackman","year":"1995","unstructured":"Jackman AL, Calvert AH (1995) Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6:871\u2013881","journal-title":"Ann Oncol"},{"key":"683_CR20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1517\/13543784.5.6.719","volume":"5","author":"AL Jackman","year":"1996","unstructured":"Jackman AL, Judson IR (1996) The new generation of thymidylate synthase inhibitors in clinical study. Expert Opin Investig New Drugs 5:719\u2013736","journal-title":"Expert Opin Investig New Drugs"},{"key":"683_CR21","first-page":"911","volume":"3","author":"AL Jackman","year":"1997","unstructured":"Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, Boyle FT (1997) Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331\u2014a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 3:911\u2013921","journal-title":"Clin Cancer Res"},{"key":"683_CR22","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1016\/0006-2952(84)90089-3","volume":"33","author":"AL Jackman","year":"1984","unstructured":"Jackman AL, Taylor GA, Calvert AH, Harrap KR (1984) Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. Biochem Pharmacol 33:3269\u20133275","journal-title":"Biochem Pharmacol"},{"key":"683_CR23","first-page":"5579","volume":"51","author":"AL Jackman","year":"1991","unstructured":"Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51:5579\u20135586","journal-title":"Cancer Res"},{"key":"683_CR24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.addr.2004.01.003","volume":"56","author":"AL Jackman","year":"2004","unstructured":"Jackman AL, Theti DS, Gibbs DD (2004) Antifolates targeted specifically to the folate receptor. Adv Drug Deliv Rev 56:1111\u20131125","journal-title":"Adv Drug Deliv Rev"},{"key":"683_CR25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-1-59259-725-3_14","volume-title":"Antifolate drugs in cancer therapy","author":"G Jansen","year":"1999","unstructured":"Jansen G (1999) Receptor- and carrier-mediated transport systems for folates and antifolates\u2014exploitation for folate-based chemotherapy and immunotherapy. In: Jackman AL (ed) Antifolate drugs in cancer therapy. Humana Press, Totowa, pp 293\u2013321"},{"key":"683_CR26","first-page":"1959","volume":"49","author":"G Jansen","year":"1989","unstructured":"Jansen G, Kathmann I, Rademaker BC, Braakhuis BJ, Westerhof GR, Rijksen G, Schornagel JH (1989) Expression of a folate binding protein in L1210 cells grown in low folate medium. Cancer Res 49:1959\u20131963","journal-title":"Cancer Res"},{"key":"683_CR27","doi-asserted-by":"crossref","first-page":"30189","DOI":"10.1074\/jbc.273.46.30189","volume":"273","author":"G Jansen","year":"1998","unstructured":"Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, Priest DG, Noordhuis P, Schornagel JH, Pinedo HM, Peters GJ, Assaraf YG (1998) A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273:30189\u201330198","journal-title":"J Biol Chem"},{"key":"683_CR28","unstructured":"Jansen G, Westerhof GR, Kathmann I, Rademaker BC, Rijksen G, Schornagel JH (1989) Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance [published erratum appears in Cancer Res 1995 Sep 15;55(18):4203]. Cancer Res 49:2455\u20132459"},{"key":"683_CR29","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1073\/pnas.83.16.5983","volume":"83","author":"BA Kamen","year":"1986","unstructured":"Kamen BA, Capdevila A (1986) Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 83:5983\u20135987","journal-title":"Proc Natl Acad Sci USA"},{"key":"683_CR30","first-page":"1641","volume":"42","author":"DA Keefe","year":"1982","unstructured":"Keefe DA, Capizzi RL, Rudnick SA (1982) Methotrexate cytotoxicity for L5178Y\/Asn-lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. Cancer Res 42:1641\u20131645","journal-title":"Cancer Res"},{"key":"683_CR31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0083-6729(03)01012-4","volume":"66","author":"LH Matherly","year":"2003","unstructured":"Matherly LH, Goldman DI (2003) Membrane transport of folates. Vitam Horm 66:403\u2013456","journal-title":"Vitam Horm"},{"key":"683_CR32","first-page":"2399","volume":"4","author":"R Mauritz","year":"1998","unstructured":"Mauritz R, Bekkenk MW, Rots MG, Pieters R, Mini E, Van Zantwijk CH, Veerman AJP, Peters GJ, Jansen G (1998) Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res 4:2399\u20132410","journal-title":"Clin Cancer Res"},{"key":"683_CR33","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1016\/S0021-9258(18)38101-8","volume":"266","author":"DE McCloskey","year":"1991","unstructured":"McCloskey DE, McGuire JJ, Russell CA, Rowan BG, Bertino JR, Pizzorno G, Mini E (1991) Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 266:6181\u20136187","journal-title":"J Biol Chem"},{"key":"683_CR34","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1016\/S0021-9258(19)70697-8","volume":"255","author":"JJ McGuire","year":"1980","unstructured":"McGuire JJ, Hsieh P, Coward JK, Bertino JR (1980) Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J Biol Chem 255:5776\u20135788","journal-title":"J Biol Chem"},{"key":"683_CR35","first-page":"317","volume":"45","author":"E Mini","year":"1985","unstructured":"Mini E, Srimatkandada S, Medina WD, Moroson BA, Carman MD, Bertino JR (1985) Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells. Cancer Res 45:317\u2013324","journal-title":"Cancer Res"},{"key":"683_CR36","first-page":"24","volume":"26","author":"RG Moran","year":"1999","unstructured":"Moran RG (1999) Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 26:24\u201332","journal-title":"Semin Oncol"},{"key":"683_CR37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/sonc.2002.37465","volume":"29","author":"C Niyikiza","year":"2002","unstructured":"Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P, Bunn PA Jr (2002) Pemetrexed safety and dosing strategy. Semin Oncol 29:24\u201329","journal-title":"Semin Oncol"},{"key":"683_CR38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0899-9007(01)00618-9","volume":"17","author":"GJ Peters","year":"2001","unstructured":"Peters GJ, Jansen G (2001) Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition 17:737\u2013738","journal-title":"Nutrition"},{"key":"683_CR39","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1042\/bst0230884","volume":"23","author":"GJ Peters","year":"1995","unstructured":"Peters GJ, Vander Wilt CL (1995) Thymidylate synthase as a target in cancer chemotherapy. Biochem Soc Trans 23:884\u2013888","journal-title":"Biochem Soc Trans"},{"key":"683_CR40","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/0959-8049(95)00172-F","volume":"31A","author":"GJ Peters","year":"1995","unstructured":"Peters GJ, Vander Wilt CL, Van Triest B, Codacci-Pisanelli G, Johnston PG, Van Groeningen CJ, Pinedo HM (1995) Thymidylate synthase and drug resistance. Eur J Cancer 31A:1299\u20131305","journal-title":"Eur J Cancer"},{"key":"683_CR41","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1158\/0008-5472.CAN-05-4048","volume":"66","author":"H Qi","year":"2006","unstructured":"Qi H, Ratnam M (2006) Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res 66:5875\u20135882","journal-title":"Cancer Res"},{"key":"683_CR42","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cell.2006.09.041","volume":"127","author":"A Qiu","year":"2006","unstructured":"Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127:917\u2013928","journal-title":"Cell"},{"key":"683_CR43","doi-asserted-by":"crossref","first-page":"C1669","DOI":"10.1152\/ajpcell.00202.2007","volume":"293","author":"A Qiu","year":"2007","unstructured":"Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, Matherly LH, Zhao R, Akabas MH, Goldman ID (2007) Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol 293:C1669\u2013C1678","journal-title":"Am J Physiol Cell Physiol"},{"key":"683_CR44","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/bi00446a042","volume":"28","author":"M Ratnam","year":"1989","unstructured":"Ratnam M, Marquardt H, Duhring JL, Freisheim JH (1989) Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry 28:8249\u20138254","journal-title":"Biochemistry"},{"key":"683_CR45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/978-1-4615-2960-6_93","volume":"338","author":"MS Rhee","year":"1993","unstructured":"Rhee MS, Galivan J, Tyobeka EM, Sherman ML, Rosowsky A (1993) Effect of a novel antifolate, N alpha-(4-amino-4-deoxypteroyl)-N delta- hemiphthaloyl-l-ornithine (PT523), on growth of H35 rat hepatoma and HEPG2 human hepatoma cells. Adv Exp Med Biol 338:461\u2013464","journal-title":"Adv Exp Med Biol"},{"key":"683_CR46","first-page":"783","volume":"45","author":"MS Rhee","year":"1994","unstructured":"Rhee MS, Galivan J, Wright JE, Rosowsky A (1994) Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Mol Pharmacol 45:783\u2013791","journal-title":"Mol Pharmacol"},{"key":"683_CR47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1083\/jcb.132.1.35","volume":"132","author":"S Rijnboutt","year":"1996","unstructured":"Rijnboutt S, Jansen G, Posthuma G, Hynes JB, Schornagel JH, Strous GJ (1996) Endocytosis of GPI-linked membrane folate receptor-alpha. J Cell Biol 132:35\u201347","journal-title":"J Cell Biol"},{"key":"683_CR48","first-page":"6513","volume":"46","author":"S Rodenhuis","year":"1986","unstructured":"Rodenhuis S, McGuire JJ, Narayanan R, Bertino JR (1986) Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res 46:6513\u20136519","journal-title":"Cancer Res"},{"key":"683_CR49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2174\/0929867306666220208214428","volume":"6","author":"A Rosowsky","year":"1999","unstructured":"Rosowsky A (1999) PT523 and other aminopterin analogs with a hemiphthaloyl-l-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates. Curr Med Chem 6:329\u2013352","journal-title":"Curr Med Chem"},{"key":"683_CR50","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2141.2000.02071.x","volume":"109","author":"MG Rots","year":"2000","unstructured":"Rots MG, Pieters R, Peters GJ, Noordhuis P, Van Zantwijk CH, Henze G, Janka-Schaub GE, Veerman AJ, Jansen G (2000) Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 109:629\u2013634","journal-title":"Br J Haematol"},{"key":"683_CR51","first-page":"4639","volume":"50","author":"BG Rumberger","year":"1990","unstructured":"Rumberger BG, Barrueco JR, Sirotnak FM (1990) Differing specificities for 4-aminofolate analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action. Cancer Res 50:4639\u20134643","journal-title":"Cancer Res"},{"key":"683_CR52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-007-9048-0","volume":"26","author":"MD Salazar","year":"2007","unstructured":"Salazar MD, Ratnam M (2007) The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26:141\u2013152","journal-title":"Cancer Metastasis Rev"},{"key":"683_CR53","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.CCR-05-9009","volume":"11","author":"GV Scagliotti","year":"2005","unstructured":"Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O\u2019Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L (2005) Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11:690\u2013696","journal-title":"Clin Cancer Res"},{"key":"683_CR54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0006-2952(94)90103-1","volume":"48","author":"JC Schmitz","year":"1994","unstructured":"Schmitz JC, Grindey GB, Schultz RM, Priest DG (1994) Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity. Biochem Pharmacol 48:319\u2013325","journal-title":"Biochem Pharmacol"},{"key":"683_CR55","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.1995.13.7.1649","volume":"13","author":"JH Schornagel","year":"1995","unstructured":"Schornagel JH, Verweij J, De Mulder PH, Cognetti F, Vermorken JB, Cappelaere P, Armand JP, Wildiers J, De Graeff A, Clavel (1995) Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and\/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol 13:1649\u20131655","journal-title":"J Clin Oncol"},{"key":"683_CR56","first-page":"1116","volume":"57","author":"C Shih","year":"1997","unstructured":"Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116\u20131123","journal-title":"Cancer Res"},{"key":"683_CR57","unstructured":"Sirotnak FM, Schmid FA, Samuels LL, DeGraw JI (1987) 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties. NCI Monogr 127\u2013131"},{"key":"683_CR58","first-page":"69","volume":"2","author":"A Smith","year":"1996","unstructured":"Smith A, Hum MC, Winick NJ, Kamen BA (1996) A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. Clin Cancer Res 2:69\u201373","journal-title":"Clin Cancer Res"},{"key":"683_CR59","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0006-2952(96)00347-4","volume":"52","author":"MJ Spinella","year":"1996","unstructured":"Spinella MJ, Brigle KE, Freemantle SJ, Sierra EE, Goldman ID (1996) Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects. Biochem Pharmacol 52:703\u2013712","journal-title":"Biochem Pharmacol"},{"key":"683_CR60","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.1074\/jbc.270.14.7842","volume":"270","author":"MJ Spinella","year":"1995","unstructured":"Spinella MJ, Brigle KE, Sierra EE, Goldman ID (1995) Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 270:7842\u20137849","journal-title":"J Biol Chem"},{"key":"683_CR61","first-page":"3612","volume":"63","author":"DS Theti","year":"2003","unstructured":"Theti DS, Bavetsias V, Skelton LA, Titley J, Gibbs D, Jansen G, Jackman AL (2003) Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Res 63:3612\u20133618","journal-title":"Cancer Res"},{"key":"683_CR62","first-page":"3675","volume":"61","author":"CL Wilt Van der","year":"2001","unstructured":"Van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ (2001) Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 61:3675\u20133681","journal-title":"Cancer Res"},{"key":"683_CR63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10637-005-4541-1","volume":"24","author":"J Walling","year":"2006","unstructured":"Walling J (2006) From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 24:37\u201377","journal-title":"Invest New Drugs"},{"key":"683_CR64","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/0006-2952(92)90089-2","volume":"44","author":"X Wang","year":"1992","unstructured":"Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M (1992) Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol 44:1898\u20131901","journal-title":"Biochem Pharmacol"},{"key":"683_CR65","first-page":"3396","volume":"52","author":"SD Weitman","year":"1992","unstructured":"Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, Kamen BA (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52:3396\u20133401","journal-title":"Cancer Res"},{"key":"683_CR66","first-page":"5507","volume":"51","author":"GR Westerhof","year":"1991","unstructured":"Westerhof GR, Jansen G, Van Emmerik N, Kathmann I, Rijksen G, Jackman AL, Schornagel JH (1991) Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res 51:5507\u20135513","journal-title":"Cancer Res"},{"key":"683_CR67","first-page":"3795","volume":"55","author":"GR Westerhof","year":"1995","unstructured":"Westerhof GR, Rijnboutt S, Schornagel JH, Pinedo HM, Peters GJ, Jansen G (1995) Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Cancer Res 55:3795\u20133802","journal-title":"Cancer Res"},{"key":"683_CR68","first-page":"459","volume":"48","author":"GR Westerhof","year":"1995","unstructured":"Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM, Jansen G (1995) Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48:459\u2013471","journal-title":"Mol Pharmacol"},{"key":"683_CR69","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/0006-2952(85)90788-9","volume":"34","author":"JC Yalowich","year":"1985","unstructured":"Yalowich JC, Kalman TI (1985) Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem Pharmacol 34:2319\u20132324","journal-title":"Biochem Pharmacol"},{"key":"683_CR70","doi-asserted-by":"crossref","unstructured":"Zervos PH, Allen RH, Thornton DE, Thiem PA (1997) Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Eur J Cancer 33(Suppl 18)","DOI":"10.1016\/S0959-8049(97)84450-4"},{"key":"683_CR71","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1158\/1078-0432.CCR-1066-03","volume":"10","author":"R Zhao","year":"2004","unstructured":"Zhao R, Gao F, Hanscom M, Goldman ID (2004) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718\u2013727","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0683-0.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T14:42:07Z","timestamp":1684248127000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0683-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,19]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0683-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,19]]}}}